Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TIL Transplant with Myeloablative Regimen in Metastatic Melanoma
NCT00096382Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Sep 2004
- Primary completion
- Jan 2009
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of therapeutic tumor-infiltrating lymphocytes in melanoma, sponsored by National Institutes of Health. Started Sep 2004; status: completed.
02
Drugs
therapeutic tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00096382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096382.